← Back to Search

Cytokine

Efmarodocokin Alfa for Graft-versus-Host Disease

Phase 1
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called Efmarodocokin Alfa to see if it can safely prevent a serious complication called acute graft-versus-host disease in patients who have had stem cell transplants. The drug is used along with standard treatments to help the body accept the new cells without causing harm.

Eligible Conditions
  • Graft-versus-Host Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Cohort C: Efmarodocokin Alfa Dosage Level 3Experimental Treatment1 Intervention
Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 3 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
Group II: Cohort B: Efmarodocokin Alfa Dosage Level 2Experimental Treatment1 Intervention
Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 2 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
Group III: Cohort A: Efmarodocokin Alfa Dosage Level 1Experimental Treatment1 Intervention
Participants undergoing allogeneic hematopoietic stem cell transplantation will receive Efmarodocokin Alfa dosage level 1 in combination with standard of care prophylaxis treatment for acute graft versus-host disease (aGVHD), consisting of tacrolimus plus methotrexate per institutional practices.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Efmarodocokin Alfa
2020
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,555 Previous Clinical Trials
569,282 Total Patients Enrolled
Clinical TrialsStudy DirectorGenentech, Inc.
2,220 Previous Clinical Trials
895,372 Total Patients Enrolled
~4 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top